2023 World Conference on Lung Cancer (Posters)-P2.13. Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients

P2.13. Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to characterize the mutational landscape of small cell lung cancer (SCLC) and examine outcomes to combination platinum-based chemotherapy and PD-L1 inhibition in real-world SCLC patients. The study included SCLC patients who underwent genomic testing using Foundation Medicine Comprehensive Genomic Profiling (CGP) tissue-based assays. The patient clinical data was obtained from a real-world clinicogenomic SCLC database originated from 280 US cancer clinics between 2011 and 2022.<br /><br />The most common genetic alterations in SCLC were mutations in TP53, followed by alterations in RB1, mutations in MLL2, alterations in PTEN, and MYCL1 amplification. The study found that patients with a high tumor mutational burden (TMB) had more favorable time to next treatment (TTNT) and overall survival (OS) when receiving first-line immunotherapy and chemotherapy. However, there was no statistically significant difference in genetic alterations between patients who had a TTNT of 6 months or less compared to those who had a TTNT of more than 6 months.<br /><br />The study suggests that a high TMB may be a prognostic factor in SCLC patients receiving chemotherapy with or without PD-L1 immune checkpoint inhibitors. However, further studies are needed to investigate additional genomic markers of chemoimmunotherapy effectiveness in SCLC, including RNA expression analysis.<br /><br />In summary, this study provides insights into the genomic associations of chemoimmunotherapy outcomes in a real-world cohort of SCLC patients. Understanding the genetic landscape of SCLC and its impact on treatment outcomes can help in the development of personalized treatment strategies for patients with this aggressive form of lung cancer.

Asset Subtitle

Ayman Ullah

Meta Tag

Speaker Ayman Ullah

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

mutational landscape

small cell lung cancer

SCLC

platinum-based chemotherapy

PD-L1 inhibition

genomic testing

TP53 mutations

RB1 alterations

MLL2 mutations

PTEN alterations